The pharmacokinetic profile of risperidone long-acting injection (RLAI) has lead to specific recommendations for its treatment initiation. A team of Mental Health Nurse Advisers conducted this audit in a cohort of 1647 patients from 32 centres in the UK to assess to what extent treatment with RLAI is initiated according to these recommendations and how this affects treatment adherence.

(BPRS). Results: The long form of MAOA demonstrated a better drug response for positive symptoms, and the short form of MAOA demonstrated a better drug response for aggression. There was a negative correlation between DRD4 VNTRS and improvement in general psychopathology. Both female patients and those with a shorter duration of the illness had a better response to olanzapine. Conclusion: The results suggest polymorphisms of MAOA and the DRD4 gene, sex, and duration of illness may be useful response predictors in schizophrenia.

No abstract